Videos

Early phase 3 results show that a single dose of MM120 can rapidly reduce anxiety symptoms in GAD patients, with effects lasting up to 12 weeks.

Psychiatric Times spoke with Altha Stewart, MD, to discuss Black history in mental health care and strides the psychiatric community is making to ensure a more inclusive future.

Mena Mirhom, MD, FAPA, introduces his new column focused on mastering media as a mental health clinician.

"She walks in beauty, like the night, Of cloudless climes and starry skies; And all that’s best of dark and bright, Meet in her aspect and her eyes..."

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how optimizing SSRI dosage, potentially augmenting with another medication class, and intensifying psychosocial support helps address breakthrough PPD symptoms in mothers with partial response to current SSRI treatment.

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how a mother's persistent PPD symptoms despite SSRI treatment necessitated a comprehensive reevaluation of medication dosage, additional therapeutic interventions, and closer monitoring of treatment response to achieve better symptom control.

Unlocking peak performance starts with the mind—Wilsa Charles Malveaux, MD, MA, FAPA, breaks the stigma around mental health in sports.

With an FDA Breakthrough Therapy Designation, what are the next steps for MM-120?

Is love a dirty word in psychiatry?

By addressing grief, loss, and sport-specific treatment needs, she helps athletes recover mentally and return to peak performance.

How best can a clinician advise their patients during hardships?

MindMed has announced the first patient has been dosed in its phase 3 study Panorama.

How has the role of the nurse practitioner changed in psychiatry?

"When she steps onto the front porch, sun shimmies through the tips of her hair, the V of her legs, fans out like wings under her arms..."

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how prompt intervention combining psychotherapy, social support mobilization, and potential medication options provides comprehensive care for the mother experiencing PPD symptoms at 12 weeks, with emphasis on both immediate symptom relief and long-term recovery strategies.

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how a mother's PPD symptoms emerged gradually through increasing anxiety, intrusive thoughts, and emotional detachment, ultimately leading her to seek professional help after her partner noticed concerning behavioral changes at 12 weeks postpartum.

Learn more about Sports Psychiatry Section Editor Wilsa M. S. Charles Malveaux, MD, MA, FAPA, and her path to sports psychiatry.

How have pharmaceutical treatments for psychiatric conditions changed in 40 years?

We need more psychiatric upstanders...

A warm welcome to Wilsa M.S. Charles Malveaux, MD, MA, FAPA, as the Psychiatric Times Sports Psychiatry Section Editor.

How have politics influenced psychiatric clinicians over the past 40 years?

"No matter, Hattie: It’s a long, beautiful walk into that flower-smothered standing ovation, so go on and make them wait."

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how postpartum depression treatments are evolving beyond traditional antidepressants to include rapid-acting options like brexanolone and zuranolone, along with enhanced screening and support programs for new mothers.

From his own recovery to leading Illinois Recovery Center, Christopher Schenewerk, MD, shares he now champions peer support, naltrexone, and long-term care.

A transformative shift in addiction treatment and advocating for evidence-based approaches like naltrexone to offer personalized recovery paths beyond traditional abstinence models may be in the future for addiction treatment.

Panelists discuss how faster-acting treatments like zuranolone might improve patient outcomes and quality of life, the initial signs to monitor for assessing effectiveness, barriers to accessing such therapies in underserved populations and strategies to increase accessibility, approaches to ensuring safety while addressing distress in patients with intrusive thoughts, effective strategies for managing sleep issues in postpartum depression (PPD), advice for the psychiatry community when treating PPD, and how to tailor advice for clinicians working with underserved populations.

Panelists discuss when to adjust the dosage of current therapies like sertraline vs considering alternative treatments and the factors that guide these decisions, as well as whether treatments with rapid onset, such as zuranolone capsules or brexanolone intravenous (IV) infusion, would be appropriate for cases like Sarah’s, and what factors would influence the choice between these options.

Panelists discuss the case of Sarah, a 29-year-old woman with a history of major depressive disorder who is struggling with postpartum adjustment and increasing isolation, highlighting the challenges of transitioning into motherhood, family dynamics, and the potential genetic and environmental factors influencing her mental health.